Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A plus concurrent chemoradiotherapy versus durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC
2021-005135-23Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-7684A arm with Durvalumab control arm (2 arms). Primary endpoint: Progression-free survival. Started Jan 2022; status: active.
02
Drugs
vibostolimab + pembrolizumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-005135-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005135-23.